Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Turcot syndrome × Immunotherapy × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 16 Carcinoma, Hepatocellular 6 Melanoma 5 Lung Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 4 Uterine Cervical Neoplasms 3 Rectal Neoplasms 3 Neoplasms 3 Neoplasm Metastasis 3 Esophageal Squamous Cell Carcinoma 3 Esophageal Neoplasms 3 Triple Negative Breast Neoplasms 2 Pathologic Complete Response 2 Pancreatic Neoplasms 2 Neoplasm, Residual 2 Hyperthermia 2 Head and Neck Neoplasms 2 Colorectal Neoplasms 2 Cholangiocarcinoma 2 Breast Neoplasms 2 Brain Neoplasms 2 Uveal Melanoma 1 Turcot syndrome 1 Small Cell Lung Carcinoma 1 Small Cell Lung Cancer Extensive Stage 1 Sarcoma 1 Recurrence 1 Radiation Pneumonitis 1 Prostatic Neoplasms 1 Pancreatic Cancer Liver Metastases 1

Interventions

Nivolumab 5 pembrolizumab 3 Neoadjuvant Therapy 3 durvalumab 2 avelumab 2 atezolizumab 2 toripalimab 1 spartalizumab 1 relatlimab 1 fludarabine phosphate 1 fludarabine 1 dostarlimab 1 danvatirsen 1 Surgical Procedures, Operative 1 Oxaliplatin 1 Leucovorin 1 Ipilimumab 1 Induction Chemotherapy 1 Immunotherapy 1 Immunoglobulin G 1 Immune Checkpoint Inhibitors 1 IMM-101 1 Fluorouracil 1 Docetaxel 1 Disulfides 1 DEAE-Dextran 1 Cyclophosphamide 1 Chemotherapy, Adjuvant 1 Celecoxib 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07259473 2026-01-07

Pre-CATALIS

Shanghai Zhongshan Hospital

Phase 2 Not yet recruiting

Turcot syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡